40180-81-2

Basic information

• Product Name: 2-(3-bromo-4-methylphenyl)propan-2-ol
• Synonyms: 2-(3-bromo-4-methylphenyl)propan-2-ol
• CAS NO: 40180-81-2
• Molecular Weight: 229.117
• Mol File: 40180-81-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-(3-bromo-4-methylphenyl)propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-bromo-4-methylphenyl)propan-2-ol(40180-81-2)
• EPA Substance Registry System: 2-(3-bromo-4-methylphenyl)propan-2-ol(40180-81-2)

Safety Data

• Hazardous Substances Data: 40180-81-2(Hazardous Substances Data)

Usage

Physical state

colorless liquid

Odor

faint

Usage

building block in organic synthesis, pharmaceutical research, and as a solvent and intermediate in the manufacturing of fragrance and flavor compounds

Derivation

bromination of 4-methylacetophenone

Importance

important intermediate in the production of various pharmaceuticals, agrochemicals, and organic compounds

Industry applications

chemical and pharmaceutical industries.

Upstream product

• 2437-76-5 2-bromo-p-cymene 
• 75-16-1 methylmagnesium bromide 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 147962-81-0 ethyl 3-bromo-4-methylbenzoate 
• 676-58-4 methylmagnesium chloride 
• 1389311-90-3 C₁₀H₁₂BrCl 

Downstream Products

• 40180-82-3 2-bromo-1-methyl-4-(prop-1-en-2-yl)benzene 
• 1345961-02-5 2-(3-bromo-4-methylphenyl)propan-2-ol 
• 1389311-90-3 C₁₀H₁₂BrCl 

Relevant articles and documents

BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.

HETEROCYCLIC DERIVATIVES AND USE THEREOF

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated

Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors

A series of gem-dimethyl-bearing C-glucosides were designed and synthesized as SGLT2 inhibitors, with anhydrous aluminum chloride-mediated Friedel-Crafts alkylation to construct the gem-dimethyl functionality being the key step. The in vivo anti-hyperglycemic activity was evaluated with mice oral glucose tolerance test (OGTT), and all the synthesized compounds showed significant but less potent anti-hyperglycemic activity than the positive control dapagliflozin.